Beta Bionics (NASDAQ:BBNX) CFO Stephen Feider Sells 20,000 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the sale, the chief financial officer owned 42,614 shares in the company, valued at $1,258,391.42. The trade was a 31.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Stephen Feider also recently made the following trade(s):

• On Tuesday, December 2nd, Stephen Feider sold 1,427 shares of Beta Bionics stock. The shares were sold at an average price of $29.34, for a total value of $41,868.18.

Beta Bionics Stock Up 1.1%

NASDAQ:BBNX opened at $29.57 on Tuesday. Beta Bionics, Inc. has a twelve month low of $8.89 and a twelve month high of $32.71. The firm has a market capitalization of $1.30 billion and a price-to-earnings ratio of -6.77. The stock’s 50 day moving average price is $29.08 and its two-hundred day moving average price is $22.01.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. The company had revenue of $27.25 million during the quarter, compared to the consensus estimate of $23.92 million. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.

Hedge Funds Weigh In On Beta Bionics

A number of large investors have recently made changes to their positions in the company. GPS Wealth Strategies Group LLC boosted its stake in Beta Bionics by 45.0% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. Strs Ohio acquired a new stake in shares of Beta Bionics during the first quarter worth $29,000. EverSource Wealth Advisors LLC boosted its position in shares of Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after acquiring an additional 1,594 shares during the period. CWM LLC acquired a new position in shares of Beta Bionics in the second quarter valued at about $58,000. Finally, Legal & General Group Plc increased its position in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after acquiring an additional 2,639 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Beta Bionics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 1st. Truist Financial upped their price objective on Beta Bionics from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Lake Street Capital reiterated a “buy” rating and set a $35.00 target price on shares of Beta Bionics in a research note on Wednesday, October 29th. The Goldman Sachs Group boosted their target price on Beta Bionics from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Bank of America raised their price target on Beta Bionics from $30.00 to $33.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $29.70.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.